ProMIS Neurosciences Inc. Common Shares (ON) - PMN STOCK NEWS

Welcome to our dedicated page for ProMIS Neurosciences Common Shares (ON) news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on ProMIS Neurosciences Common Shares (ON) stock.

ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company dedicated to discovering and developing precision therapeutics and companion diagnostics for neurodegenerative diseases such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Leveraging its proprietary target discovery engine, ProMIS™ and Collective Coordinates, the company aims to predict novel targets on misfolded proteins, known as Disease Specific Epitopes (DSEs), to create highly selective antibody therapeutics.

ProMIS Neurosciences is advancing its lead product, PMN310, a humanized IgG1 antibody designed to selectively target toxic amyloid-beta oligomers, believed to be a major driver of AD. PMN310's distinctive approach potentially improves efficacy and reduces the risk of amyloid-related imaging abnormalities (ARIA), a common side effect in other amyloid-beta-directed therapies. The product is currently in Phase 1a clinical trials, with initial safety and pharmacokinetic data expected by mid-2024.

In addition to Alzheimer's disease, ProMIS is developing PMN267, a humanized IgG1 antibody targeting misfolded TDP-43 proteins in ALS. Preclinical data have shown that PMN267 helps mitigate neurodegeneration by targeting the pathogenic interaction between TDP-43 and SOD1 in ALS.

ProMIS is also focusing on therapeutic targets for multiple synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and MSA. The company's pipeline includes a computationally-derived amyloid-beta vaccine for AD and multiple earlier-stage antibody candidates for other neurodegenerative conditions.

Recent achievements include the publication of preclinical data supporting PMN267 as a potential ALS treatment in the Journal of Biological Chemistry and the identification of RACK1 as a novel target for ALS and frontotemporal lobar degeneration (FTLD). The company has also secured key U.S. and international patents to protect its intellectual property, particularly around PMN310, which further validates its innovative approach to treating neurodegenerative diseases.

With offices in Toronto, Ontario, and Cambridge, Massachusetts, ProMIS Neurosciences continues to build on its robust scientific foundation focused on tackling diseases characterized by abnormal, misfolded proteins. The company aims to advance clinical development across its therapeutic pipeline while maintaining a tight control on cash management, ensuring the sustainability of its operations and long-term growth.